Dyne Therapeutics, Inc. (NASDAQ:DYN) SVP Sells $73,162.76 in Stock

Dyne Therapeutics, Inc. (NASDAQ:DYN - Get Free Report) SVP Richard William Scalzo sold 2,588 shares of Dyne Therapeutics stock in a transaction dated Thursday, May 16th. The shares were sold at an average price of $28.27, for a total value of $73,162.76. Following the completion of the transaction, the senior vice president now directly owns 116,695 shares of the company's stock, valued at $3,298,967.65. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Richard William Scalzo also recently made the following trade(s):

• On Monday, March 11th, Richard William Scalzo sold 2,672 shares of Dyne Therapeutics stock. The shares were sold at an average price of $25.28, for a total value of $67,548.16.
• On Thursday, March 7th, Richard William Scalzo sold 2,273 shares of Dyne Therapeutics stock. The shares were sold at an average price of $25.85, for a total value of $58,757.05.
• On Thursday, February 29th, Richard William Scalzo sold 3,429 shares of Dyne Therapeutics stock. The stock was sold at an average price of $27.50, for a total value of $94,297.50.

Dyne Therapeutics Stock Performance

NASDAQ DYN traded down $1.07 during trading on Friday, hitting $27.68. The stock had a trading volume of 1,318,228 shares, compared to its average volume of 1,771,690. The company has a market capitalization of $2.42 billion, a PE ratio of -6.97 and a beta of 1.00. The company's 50-day moving average price is $26.58 and its two-hundred day moving average price is $19.80. Dyne Therapeutics, Inc. has a 12 month low of $6.40 and a 12 month high of $30.27.

Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last released its quarterly earnings data on Thursday, May 2nd. The company reported ($0.81) EPS for the quarter, meeting the consensus estimate of ($0.81). As a group, equities analysts anticipate that Dyne Therapeutics, Inc. will post -3.1 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

DYN has been the subject of several analyst reports. Oppenheimer restated an "outperform" rating and set a $47.00 target price on shares of Dyne Therapeutics in a research report on Monday, May 6th. Chardan Capital reiterated a "buy" rating and set a $31.00 price objective on shares of Dyne Therapeutics in a report on Monday, May 6th. Piper Sandler lifted their price objective on Dyne Therapeutics from $27.00 to $29.00 and gave the company an "overweight" rating in a report on Wednesday, March 6th. Stifel Nicolaus lifted their price objective on Dyne Therapeutics from $35.00 to $41.00 and gave the company a "buy" rating in a report on Wednesday, March 6th. Finally, Morgan Stanley assumed coverage on Dyne Therapeutics in a report on Tuesday, April 30th. They set an "overweight" rating and a $40.00 price objective on the stock. One analyst has rated the stock with a sell rating, seven have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $37.75.

Institutional Investors Weigh In On Dyne Therapeutics

Several large investors have recently made changes to their positions in DYN. Wetzel Investment Advisors Inc. acquired a new stake in Dyne Therapeutics during the 1st quarter valued at $28,000. Ameritas Investment Partners Inc. lifted its holdings in Dyne Therapeutics by 28.0% during the 1st quarter. Ameritas Investment Partners Inc. now owns 5,896 shares of the company's stock valued at $167,000 after purchasing an additional 1,291 shares during the last quarter. China Universal Asset Management Co. Ltd. lifted its holdings in Dyne Therapeutics by 355.6% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 7,099 shares of the company's stock valued at $94,000 after purchasing an additional 5,541 shares during the last quarter. EntryPoint Capital LLC acquired a new stake in Dyne Therapeutics during the 1st quarter valued at $214,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank increased its position in Dyne Therapeutics by 58.5% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 8,379 shares of the company's stock worth $75,000 after buying an additional 3,092 shares during the period. Institutional investors and hedge funds own 96.68% of the company's stock.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.